Concepts (84)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| NAV1.6 Voltage-Gated Sodium Channel | 11 | 2026 | 27 | 3.700 |
Why?
|
| Fibroblast Growth Factors | 8 | 2025 | 172 | 2.360 |
Why?
|
| NAV1.2 Voltage-Gated Sodium Channel | 2 | 2026 | 9 | 1.660 |
Why?
|
| Peptidomimetics | 3 | 2021 | 11 | 1.510 |
Why?
|
| Nucleus Accumbens | 3 | 2025 | 55 | 1.260 |
Why?
|
| Neurons | 7 | 2026 | 1979 | 1.080 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2026 | 32 | 0.960 |
Why?
|
| Malaria, Cerebral | 1 | 2023 | 4 | 0.820 |
Why?
|
| Illness Behavior | 1 | 2023 | 7 | 0.820 |
Why?
|
| HEK293 Cells | 9 | 2026 | 801 | 0.800 |
Why?
|
| Protein Domains | 2 | 2025 | 252 | 0.700 |
Why?
|
| Macromolecular Substances | 1 | 2021 | 130 | 0.690 |
Why?
|
| Alzheimer Disease | 2 | 2026 | 878 | 0.690 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 3 | 2026 | 62 | 0.680 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2021 | 40 | 0.650 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 219 | 0.650 |
Why?
|
| Signal Transduction | 3 | 2026 | 4686 | 0.580 |
Why?
|
| Protein Binding | 7 | 2026 | 1652 | 0.520 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 710 | 0.510 |
Why?
|
| Molecular Docking Simulation | 4 | 2026 | 161 | 0.410 |
Why?
|
| Mice | 9 | 2026 | 18301 | 0.330 |
Why?
|
| Allosteric Regulation | 2 | 2021 | 57 | 0.320 |
Why?
|
| Animals | 12 | 2026 | 33912 | 0.310 |
Why?
|
| Drug Design | 2 | 2020 | 156 | 0.300 |
Why?
|
| NAV1.7 Voltage-Gated Sodium Channel | 1 | 2025 | 3 | 0.230 |
Why?
|
| Drug-Seeking Behavior | 1 | 2025 | 7 | 0.230 |
Why?
|
| Nociception | 1 | 2025 | 12 | 0.230 |
Why?
|
| Action Potentials | 3 | 2025 | 476 | 0.220 |
Why?
|
| Behavior, Animal | 2 | 2025 | 480 | 0.220 |
Why?
|
| Tretinoin | 1 | 2025 | 95 | 0.220 |
Why?
|
| Diabetic Neuropathies | 1 | 2025 | 56 | 0.220 |
Why?
|
| Axin Protein | 1 | 2025 | 32 | 0.220 |
Why?
|
| Sensory Receptor Cells | 1 | 2025 | 61 | 0.220 |
Why?
|
| Ion Channel Gating | 2 | 2021 | 119 | 0.210 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2023 | 34 | 0.200 |
Why?
|
| Structure-Activity Relationship | 2 | 2021 | 552 | 0.180 |
Why?
|
| Emotions | 1 | 2025 | 350 | 0.180 |
Why?
|
| Motivation | 1 | 2025 | 328 | 0.180 |
Why?
|
| Allosteric Site | 1 | 2021 | 12 | 0.170 |
Why?
|
| Disease Models, Animal | 3 | 2026 | 4697 | 0.170 |
Why?
|
| Humans | 13 | 2026 | 131163 | 0.160 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2020 | 61 | 0.160 |
Why?
|
| Oligopeptides | 1 | 2020 | 101 | 0.160 |
Why?
|
| Amino Acid Sequence | 2 | 2021 | 2395 | 0.160 |
Why?
|
| Protein Structure, Secondary | 1 | 2020 | 235 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 633 | 0.150 |
Why?
|
| Molecular Structure | 1 | 2020 | 315 | 0.150 |
Why?
|
| Hippocampus | 2 | 2022 | 806 | 0.150 |
Why?
|
| Drug Discovery | 1 | 2021 | 179 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 480 | 0.150 |
Why?
|
| Janus Kinase 2 | 1 | 2020 | 138 | 0.140 |
Why?
|
| Protein Conformation | 1 | 2021 | 732 | 0.140 |
Why?
|
| Computer Simulation | 1 | 2021 | 674 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 2 | 2025 | 4738 | 0.130 |
Why?
|
| Binding Sites | 1 | 2020 | 1133 | 0.130 |
Why?
|
| Models, Molecular | 1 | 2020 | 1064 | 0.130 |
Why?
|
| Rats | 3 | 2026 | 3370 | 0.110 |
Why?
|
| Patch-Clamp Techniques | 2 | 2025 | 271 | 0.090 |
Why?
|
| Pyramidal Cells | 2 | 2022 | 151 | 0.080 |
Why?
|
| Phosphorylation | 2 | 2025 | 1571 | 0.070 |
Why?
|
| Male | 5 | 2026 | 64957 | 0.070 |
Why?
|
| Mutation | 1 | 2021 | 6099 | 0.070 |
Why?
|
| Retinal Dehydrogenase | 1 | 2025 | 18 | 0.060 |
Why?
|
| Self Administration | 1 | 2025 | 49 | 0.060 |
Why?
|
| TRPV Cation Channels | 1 | 2025 | 42 | 0.060 |
Why?
|
| Fentanyl | 1 | 2025 | 53 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 1 | 2025 | 378 | 0.050 |
Why?
|
| Reward | 1 | 2025 | 140 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2025 | 229 | 0.050 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2025 | 238 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2025 | 1105 | 0.050 |
Why?
|
| Genetic Complementation Test | 1 | 2020 | 89 | 0.040 |
Why?
|
| Luciferases | 1 | 2020 | 127 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2025 | 863 | 0.040 |
Why?
|
| Phosphotyrosine | 1 | 2020 | 30 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2020 | 92 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2025 | 2326 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2020 | 148 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 119 | 0.040 |
Why?
|
| Ligands | 1 | 2020 | 481 | 0.040 |
Why?
|
| Anxiety | 1 | 2025 | 1014 | 0.030 |
Why?
|
| Phenotype | 1 | 2025 | 4497 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2904 | 0.020 |
Why?
|
| Female | 1 | 2025 | 70963 | 0.010 |
Why?
|